FIELD: medicine.
SUBSTANCE: invention refers to biotechnology, virology and medicine. The method provides administering a pox virus containing the defect F2L gene into a host body or a cell. What is also described is using this pox virus for producing a drug preparation for treating proliferative diseases or diseases accompanied by osteoclast hyperactivity. The invention can be used in medicine.
EFFECT: what is presented is the method of treating proliferative diseases or diseases accompanied by osteoclast hyperactivity.
28 cl, 10 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2508401C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2503717C2 |
| RECOMBINANT VARIOLOVACCINE VIRUS STRAIN VV-NS1-dGF PRODUCING NS1 PARVOVIRUS H-1 PROTEIN AND HAVING ONCOLYTIC ACTIVITY ON HUMAN GLIOBLASTOMA | 2018 |
|
RU2692628C1 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS | 2015 |
|
RU2705780C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| RECOMBINANT STRAIN VV-GMCSF-Lact OF VACCINIA VIRUS, HAVING ONCOLYTIC ACTIVITY AND PRODUCING GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR AND ONCOTOXIC LACTAPTIN PROTEIN | 2015 |
|
RU2604187C1 |
| RECOMBINANT STRAIN OF VV-GMCSF-S-Lact VACCINIA VIRUS, WITH ONCOLYTIC ACTIVITY, PRODUCING GRANULOCYTOR-MACROPHAGAL COLONY-STIMULATING HUMAN FACTOR AND SECRETED FORM OF LACTAPTIN ONCOTOXIC PROTEIN | 2016 |
|
RU2621861C1 |
| RECOMBINANT ONCOLYTIC STRAIN OF THE VACCINIA VIRUS L-IVP_ONCOB, CONTAINING GENES, ENCODING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND POLYEPITOPE IMMUNOGEN, CONSISTING OF EPITOPES OF ANTIGENS, HYPER EXPRESSING BY TUMOR CELLS IN BREAST CANCER | 2017 |
|
RU2678056C1 |
